Serum cortisol in the early postoperative period as predictor of remission in Cushing's disease

Oliveira J1,4,5, Lau E1,4,5, Belo S1,4,5, Freitas P1,4,5, Vinha E1,4, Pereira J2,4, Castro L3,4, Carvalho D1,4,5

1Endocrinology, Diabetes and Metabolism Department; 2Neurosurgery Department; 3Pathological Anatomy Department; 4Centro Hospitalar São João, Porto, Portugal; 5Faculty of Medicine of University of Porto, Portugal

Introduction
Pituitary surgery is currently considered the preferred treatment for Cushing’s disease (CD) and achieves remission in 55-85% of patients. Cortisol falls after surgery, so that early postoperative cortisol level has been used as predictor of remission. There’s no agreement about optimal timing for cortisol measurement, with wide variability between centers.

Objective
To assess the value of early (24 hours) postoperative serum cortisol as predictor of remission after pituitary surgery in Cushing’s disease.

Methods
Cross-sectional, retrospective study of patients who underwent pituitary surgery for CD between January/1998-October/2013. No glucocorticoid replacement therapy was initiated until blood samples were drawn (8 a.m. the day after surgery).

✓ Serum cortisol (normal range: 7-25 μg/dL), ACTH (normal range: <63.3 ng/L), urinary free cortisol (normal range: 75-270 μg/24h).
✓ Remission was defined as restitution of normocortisolemia or development of hypocortisolism requiring glucocorticoid replacement.

Results

<table>
<thead>
<tr>
<th>Insufficient data</th>
<th>45 patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>53 patients</td>
</tr>
<tr>
<td>Age (years, mean (SD))</td>
<td>36.2 (12.9)</td>
</tr>
<tr>
<td>Sex [%]</td>
<td>Male: 6 (13.3%); Female: 39 (86.7%)</td>
</tr>
<tr>
<td>Follow-up (months, mean (SD))</td>
<td>90.4 (50.7)</td>
</tr>
</tbody>
</table>

**After pituitary surgery:**

✓ 33 patients (73.3%) achieved cure
✓ 12 patients (26.7%) presented persistent disease
✓ 10 patients relapsed (30.3%) mean follow-up time until relapse of 64.4 ± 36 months

**Basal hormonal measurements**

<table>
<thead>
<tr>
<th>ACTH [ng/L, mean (SD)]</th>
<th>75.9 (41.3) (n=40)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum cortisol [μg/dL, mean (SD)]</td>
<td>27.5 (10.9) (n=59)</td>
</tr>
<tr>
<td>Urinary free cortisol [μg/24h, mean (SD)]</td>
<td>456.3 (406.2) (n=40)</td>
</tr>
<tr>
<td>Cortisol – Overnight dexamethasone suppression test [μg/dL, mean (SD)]</td>
<td>22.8 (15.5) (n=12)</td>
</tr>
</tbody>
</table>

**CRH test**

17 patients

60.2% (n=10) Inconclusive
18.8% (n=3) Pituitary origin
21.0% (n=4) Non-invasive

**Magnetic resonance imaging**

43 patients

63.3% (n=23) Invasive adenoma
18.6% (n=8) Microadenoma
1.1% (n=2) Atypical-adenoma
4.7% (n=2) Non-adenoma

**Inferior petrosal sinus sampling**

12 patients

5.8% (n=1) No sinus flow
29.5% (n=3) Non-diagnostic
60.7% (n=8) Diagnostic

**Histology**

45 patients

83.2% (n=37) ACTH-producing adenoma
17.8% (n=8) No adenoma identified

**Discussion/Conclusion**

Previous studies demonstrated that some patients have a delayed decrease to normal or low cortisol levels, without immediate postoperative remission. That could be explained by a gradual resolution of adrenal autonomy after pituitary adenoma resection, especially in the presence of significant bilateral hyperplasia. Moreover, gradual decline in cortisol during early postoperative period could be related to delayed adenoma necrosis. In our cohort, serum cortisol measured at 24 hours after pituitary surgery was not predictive of remission of CD. A longer interval between surgery and hormonal evaluation may allow a more accurate classification of these patients, including those with later remission.

Despite this difference, the postoperative serum cortisol was not a good predictor of remission of CD (AUC<0.5).

No significant differences in urinary free cortisol, ACTH, serum cortisol and cortisol in the overnight dexamethasone suppression test at diagnosis between patients with and without disease remission after surgery, or between patients with and without disease recurrence.